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Abstract The use of topical preparations for symp-
tom relief is common in osteoarthritis. The eVects of
ibuprofen (5%) and arnica (50 g tincture/100 g, DER
1:20), as gel preparations in patients with radiologically
conWrmed and symptomatically active osteoarthritis of
interphalangeal joints of hands, were evaluated in a
randomised, double-blind study in 204 patients, to
ascertain diVerences in pain relief and hand function
after 21 days’ treatment. Diagnosis was according to
established criteria; primary endpoints were pain
intensity and hand function; statistical design was as
per current regulatory guidelines for testing topical
preparations. There were no diVerences between the
two groups in pain and hand function improvements,
or in any secondary end points evaluated. Adverse
events were reported by six patients (6.1%) on ibupro-
fen and by Wve patients (4.8%) on arnica. Our results
conWrm that this preparation of arnica is not inferior to
ibuprofen when treating osteoarthritis of hands.
Keywords Osteoarthritis · Ibuprofen gel · Arnica gel · 
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Introduction
Osteoarthritis (OA) is one of the most common joint
disorders aVecting mature adults and the elderly, in
whom the prevalence of hand symptoms ranges from
13% (men) to 26% (women), according to the Fra-
mingham Study [1]. The commonest aVected joints are
the distal interphalangeal (DIP) followed by proximal
interphalangeal (PIP) and the metacarpal–phalangeal
(MCP) joints, with gradual cartilage destruction associ-
ated with development of nodule-like swellings on
both sides of the joints (Heberden and Bouchard nodes
for DIP and PIP, respectively). Swelling and redness
are usually mild but may be accompanied by severe
pain and increasing functional impairment [2].
Current treatment is essentially supportive and
symptomatic [3], as there is no available therapy to
reverse or halt the natural progression of OA. Analge-
sics and non-steroidal anti-inXammatory drugs (NSA-
IDs) such as ibuprofen and diclofenac remain the
mainstay of drug treatment. Ibuprofen, in use for over
forty years, has been shown to relieve OA symptoms
eVectively [4] and intra-articular steroids and hyal-
uronic acid derivatives are also used, whilst physiother-
apy and other supportive care have been shown to
improve function [3]. Topical use of NSAIDs reduces
systemic adverse eVects, particularly on the gastroin-
testinal (GI) tract [5] and a meta-analysis of 86 placebo
controlled studies (10,160 patients) conWrmed the ben-
eWts of various topical agents [6], while ibuprofen gel
5% has been shown to be eVective in musculoskeletal
injuries [7, 8], tendonitis [9], general osteoarthritis [10]
and osteoarthritis of the knee and Wnger joints [11, 12].
Drug penetration and bioavailability of ibuprofen
gel 5% in muscle and connective tissue beneath the
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586 Rheumatol Int (2007) 27:585–591application site are in the same order of magnitude as
after oral administration [13, 14].
Topical phytotherapy preparations such as extracts
of willow bark, devil’s claw, capsicum and arnica are
also frequently used [15]. Arnica montana L (other
names are: arnica, mountain tobacco, medicinal leop-
ard’s bane; mountain alkanet) has been used as a topi-
cal agent since at least the sixteenth century [16], and
nowadays most frequently for the treatment of contu-
sions and sprains, or for symptomatic relief in OA [17].
We stipulated three pre-conditions for choosing the
arnica preparation amongst the numerous available.
Firstly, the preparation had to have published evidence
from preclinical studies of some anti-inXammatory
action, secondly the preparation had to have published
evidence of skin penetration and, thirdly it had to be
available as gel and should be as similar as possible to
ibuprofen gel, to ensure blindness during the study.
Our chosen preparation has shown evidence of com-
plete inhibition of the transcription factor NF-kappaB
by arnica constituents (sesquiterpene lactone helenalin,
11,13-dihydrohelenalin and its ester) [18], which is
similar to the eVects of glucocorticoids on inXammatory
cascade [19], as well as skin penetration [20]. In appear-
ance, arnica gel was indistinguishable from ibuprofen.
Materials and methods
Patient selection and blinding
We enrolled patients from 20 clinics (12 general
practices, 6 rheumatology clinics, 2 general medicine)
in three Swiss cantons (Zurich, St Gallen and Aargau)
between May 2003 and March 2004. A total of 204
patients were enrolled, of whom 198 were included in
the intention-to-treat (ITT) analysis and a further 24
patients were excluded from the per protocol (PP)
analysis (Table 1). Diagnosis was according to estab-
lished criteria [21]. Patient selection was conducted
according to the Osteoarthritis Research Society Inter-
national (OARSI) guidelines [22] and their recommen-
dations for studying polyarthritis of Wnger joints, and
the European Medicines Agency (EMEA) guidelines
on choice of controlled studies and statistical design
regarding gel evaluations [23, 24]. The study was con-
ducted according to Good Clinical Practice guidelines
and the Declaration of Helsinki, and approved by the
relevant Ethics Committees and Swiss regulatory
authorities.
Patients were initially screened and, if considered
eligible and consented, they were randomised to one of
the two treatment groups (ibuprofen or arnica). The
protocol selection criteria are summarised in Table 2.
Before being dispensed treatment, patients were fully
medically evaluated. Both treatments were to be used
in identical dispensing doses of gel (4 cm strip), gently
rubbed over the aVected joints thrice-daily for 3 weeks,
and were asked not to wash hands for one hour after
application. Patients were dispensed a preset number
of paracetamol tablets (20 £ 500 mg tablets) as
“escape treatment” (not allowed within 24 h prior to
the Wnal evaluation) and asked to return any unused
tablets at the end of the treatment course. For patients
on long-term low-dose aspirin for cardiovascular con-
ditions, 325 mg daily maximum was allowed.
Table 1 Disposition, demo-
graphics and status of patients 
in the study
Ibuprofen gel Arnica gel
Randomized (n) 99 – 105 –
Excluded at baseline visit (n) 1 – 5 –
ITT Population (n, %) 98 100.0 100 100.0
Treatment duration <18 or >26 days (n, %) 6 5.9 3 3.0
Use of (excluded) analgesics (n, %) 2 2.0 2 2.0
No per protocol radiological evidence (n, %) 2 2.0 2 2.0
Hand function <5 (HAI) or Pain <4 (VAS) (n, %) 2 2.0 2 2.0
Early intolerance of gel (n, %) 1 1.0 2 2.0
Total exclusions (n, %) 13 12.7 11 11.0
Per protocol population (n, %) 85 83.3 89 89.0
Age (years; mean, SD) 64 11.4 64 12.0
Females (n, % PP population) 72 61.2 75 66.8
Weight (kg; mean, SD) 71 13.3 70 13.4
AVected Wngers (n; mean, SD) 7 2.1 7 2.0
AVected joints (n; mean, SD) 11 4.1 11 5.0
Hand algofunctional index (mean, SD) 12 3.3 11 4.0
Pain intensity (VAS; mean, SD) 68 14.2 67 14.4
Painful joints (n; mean, SD) 8 4.6 9 4.9
Morning stiVness intensitya (mean, SD) 3 0.9 3 0.8
Morning stiVness durationb (mean, SD) 4 1.1 4 1.0
No statistical diVerence be-
tween groups in any demo-
graphic or status parameters 
at baseline
a Mean value of 1 none, 2 
slight, 3 moderate, 4 severe, 5 
extreme morning stiVness
b Mean value of 1 none, 2 up 
to 2 min, 3 up to 5 min, 4 up to 
10 min, 5 more than10 min123
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Spirig Pharma Ltd, and Arnica Gel (A. Vogel Arnica
Gel®; Arnica montana fresh herbal tincture 50 g/100 g
gel; drug-to-extract ratio (DER) of the tincture 1:20)
was supplied by Bioforce AG.
Statistics
The aim of the study was to evaluate the eYcacy and
tolerability of arnica gel compared to ibuprofen gel 5%
in the treatment of OA of the Wngers using the
approach (non-inferiority) suggested by current guid-
ance on comparisons of gel preparations [23, 24]. Ran-
domisation codes were computer-generated in blocks
of four (RanCode, Version 3.6, IDV-Gauting, Ger-
many). Double-blindness was assured by identical
packaging (100 ml tubes), as well as gel appearance
and consistency. There was a slight diVerence in odour
for the Wrst 30 s after application, after which both
were odourless. We considered this of no practical con-
sequence for blindness because patients only received
one of the treatments, so they were not aware of the
comparator.
The primary eYcacy parameters were: (a) reduction
in pain, recorded as the most intense in the previous
24 h, in the worst aVected Wnger, on VAS (100 mm) by
the patient and; (b) functional capacity of the hand
using the validated HAI assessment (Table 3) [25]. The
secondary parameters were: (a) number of painful
joints (DIPs, PIPs and MCPs) in both hands; (b) inten-
sity of morning stiVness in the worst aVected hand; (c)
duration of morning stiVness in the worst aVected
hand; (d) analgesic consumption; (e) patients’ and doc-
tors’ global evaluation of eYcacy; (f) patients’ accep-
tance of the gel treatment. Safety was to be evaluated
by adverse event monitoring.
Non-inferiority (arnica relative to ibuprofen) was set
as the diVerence being not greater than 12% in each of
Table 2 Patient selection 
Inclusion criteria
Patients of either gender
Age between 18 and 88 years, inclusive
Osteoarthritis diagnosis according to ARC criteria (modiWed by Altman) [21] 
(a): pain or stiVness in the hands or Wngers on most days during the previous month 
(b) hard tissue enlargement in ¸2 of ten joints (DIP and PIP joints II/III as well as 
both carpal-metacarpal joints)
(c) less than two swollen MCP joints 
(d) ¸1 DIP joint with hard tissue enlargement or ¸1 of the joints referred to under (b)
In addition, the following criteria applied for the worst aVected hand
Pain intensity of on the Visual Analogue Scale (VAS 0–100 mm) of at least 40 mm in the Wnger 
joint with the worst possible spontaneous pain in the previous 24 h
At least 5 points, measured on the Hand Algofunctional Index (HAI)
Radiological conWrmation of osteoarthritis in ¸2 joints with radiographs ·3 months old and ¸1 
painful joint conWrmed radiologically
Discontinuation of all NSAIDs (topical and systemic) >10 days prior to entry
Discontinuation of all analgesics >3 days prior to entry
Written Informed consent
Exclusion criteria
Secondary osteoarthritis (due to causes other than solely degenerative joint disease)
Trauma to the hand or arm in the previous 2 months
Residual pain following fracture, dislocation or operation
Pain and stiVness due to tissue scarring
Tendinitis
Carpal tunnel or other nerve compression syndromes
Serious conditions, such as cancer, uncontrolled hypertension or heart failure
Systemic or intra-articular corticosteroids in the previous month and during study
Damaged skin or serious skin disorders aVecting hands
Allergy to Asteraceae
Intolerance to paracetamol
Table 3 Hand algofunctional index
Scores: 0 possible without diYculty; 1 possible with slight diY-
culty; 2 possible with signiWcant diYculty; 3 impossible
1. Are you able to turn a key in a lock?
2. Are you able to cut meat with a knife?
3. Are you able to cut cloth or paper with a pair of scissors?
4. Are you able to lift a full bottle with one hand?
5. Are you able to clench a Wst?
6. Are you able to tie a knot?
7a. For women: Are you able to sew?
7b. For men: Are you able to use a screwdriver?
8. Are you able to fasten buttons?
9. Are you able to write for a long period of time?
10. Would you accept a handshake without reluctance?123
588 Rheumatol Int (2007) 27:585–591the two main assessment tools, which corresponds to
3.6 points on HAI (for hand function) and 12 mm on
the VAS (for pain), hence a standardised diVerence
(eVect size) of 0.66. A standard deviation of 5.5 was
derived from the validation data of HAI [25]. The
Mann–Whitney statistic P(X < Y) was used as a mea-
sure of relevance for the diVerence, hence:
P(X < Y) < 0.5 (inferiority); P(X < Y) = 0.5 (no diVer-
ence); P(X < Y) > 0.5 (superiority). The Mann–Whit-
ney statistics (for an eVect size of 0.66) corresponds to
P(X < Y) = 0.322.
Non-inferiority of arnica was to be formally shown
when the left margin of the one-sided -conWdence
limit of the Mann–Whitney statistic was greater than
0.322. In a Wrst step, H01 was tested
(arnica < ibuprofen for combined pain and hand func-
tion). If the left margin of the one-sided -conWdence
limit were greater than 0.322, then hypotheses H02 and
H03 (arnica < ibuprofen for pain and hand function,
respectively) were tested, maintaining the global level
of signiWcance (closed test principle).
Sample size calculation was based on an assumption
that the diVerence between the two treatments would
be not more than ¡1 point on HAI. Thus, with a stan-
dard deviation of 5.5, a one-sided t-test with signiW-
cance level of alpha = 0.024 and 80% power gives a
sample size of 73 patients per group to reject the null
hypothesis (inferiority of arnica). Since the power of
the Wilcoxon test is slightly inferior to that of t-test (for
a normal distribution), a minimum of 80 assessable
cases (per protocol) were required. An interim analysis
was planned for possible adjustment of sample size
after 60 patients were entered, for which the statistical
tests were adjusted accordingly and the conWdence
interval was restricted to 95.2%. No adjustments were
required to the sample size during the interim analysis.
An ITT analysis was to be conducted similarly to the
PP analysis but including all randomised patients who
had used the gel at least once and who had a post-base-
line value for comparison. The safety analysis was to be
conducted in all patients who used treatment at least
once.
Results
On entry, there were no diVerences between groups
regarding any demographic or disease parameter
(Table 1).
Pain intensity and hand function were similarly
improved in both treatment groups, the diVerences
being within the 95.2% conWdence intervals and the
inferiority thresholds (Table 4). The generalised Wil-
coxon’s test for the treatment diVerence was above the
deWned non-inferiority threshold of 0.322. Thus, the
Wrst hypothesis that arnica is inferior to ibuprofen in
terms of both target parameters (function and pain)
was rejected and the two criteria could be tested for the
one-sided level  = 0.024, which showed the left limit of
the respective two-sided 95.2% conWdence regions also
greater than 0.322 for the two individual parameters, so
the inferiority hypothesis was not proven for the two
criteria. Results from the analysis of the ITT popula-
tion were essentially identical to those of the PP popu-
lation.
The results were also similar for both groups for all
secondary parameters (Table 4). Mean (§SD) paracet-
amol consumption as “escape treatment” was
11.3 § 7.2 and 11.2 § 6.8 tablets (ibuprofen and arnica,
respectively) during the 3 weeks.
Global eYcacy evaluation by physicians was very
good or good in 56.5% (ibuprofen) and 64.0% (arnica),
while patients rated eYcacy very good or good in
58.8% (ibuprofen) and 64.1% (arnica) of cases
(Table 5). Patients’ acceptance of the gel treatment
was 76.5 and 78.7% (very satisWed or satisWed; ibupro-
fen and arnica, respectively) (Fig. 1).
Both treatments were well tolerated by patients,
with 6.1 and 4.8% of patients on ibuprofen and arnica,
respectively, reporting a treatment-related adverse
event. The skin was the main target organ for events
(Table 6). There was one serious event (back trauma
due to fall), not related to treatment (arnica).
Discussion
Although a multitude of topical gel preparations for
OA of peripheral joints are used by patients and pre-
scribed by doctors, we set out to evaluate whether
there was a noticeable diVerence between a commonly
used synthetic NSAID and a traditional phytothera-
peutic, when tested by objective methods using vali-
dated assessment tools, and according to the
perceptions of doctors and patients. Our results dem-
onstrate that topical arnica gel is not inferior to ibupro-
fen gel, regarding hand functional capacity, pain
intensity, number of painful joints, duration and sever-
ity of morning stiVness, or paracetamol consumption.
Importantly, not only were improvements in all param-
eters similar, they were also clinically relevant. When
blinded to treatment, neither patients nor doctors can
distinguish between the eVects of these two treatments.
There were some limitations in our study, but these
were minor and did not aVect the plausibility of the
results. Firstly, although similar in every other way123
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ties), blinding of the gels could be argued to have been
sub-optimal because they emanated slightly diVerent
odours during the Wrst 30 s of application. We feel this
cannot have had a major inXuence in the results,
because patients were only given one of the treatments
and they were to be used at home. Should we have
used a cross-over design (where each individual would
be exposed to both gels), this might have had an inXu-
ence on results. Secondly, despite our best eVorts, we
lost six patients from follow up for the ITT analysis.
One has to consider that patients with chronic, non-life
threatening conditions have slightly lower attendance
compliance than those with serious illnesses. However,
this was a very small number relative to the overall
sample (n = 204) and it is highly unlikely that the ITT
results would have changed in substance, if their post-
baseline data were obtainable.
Consumption of paracetamol was strictly controlled
and comparable in both groups. Yet, we were cautious
to ensure even the “escape treatment” was discontin-
ued 24 h before the Wnal evaluation, to prevent an anal-
gesic carry-over eVect.
A review of topical NSAIDs indicated some supe-
riority relative to placebo, particularly in soft tissue
disorders, as well as equivalent eYcacy when com-
pared with some orally administered NSAIDs,
although the literature was not very robust. The
safety proWle was acceptable (2% self-limiting skin
events). The cost–beneWt analysis showed an initial
higher cost for topical treatments but also an overall
beneWt [26].
Two meta-analysis of randomised trials with topical
application of NSAIDs, one in osteoarthritis and
rheumatoid [5] and one of osteoarthritis [27] showed
superiority to placebo in pain reduction with short-term
Table 4. Results
PP Per protoco, ITT intention to treat, HAI hand algofunctional index, VAS visual analogue scale
a Mean value of 1 none, 2 slight, 3 moderate, 4 severe, 5 extreme morning stiVness
b Mean value of 1 none, 2 up to 2 min, 3 up to 5 min, 4 up to 10 min, 5 more than10 min
Main endpoints Pain (VAS) Hand function (HAI)
Ibuprofen gel 
(n = 85)
Arnica gel 
(n = 89)
Ibuprofen gel 
(n = 85)
Arnica gel 
(n = 89)
PP population
Day 0: mean (SD) 68.0 (14.2) 66.9 (14.4) 12.1 (3.3) 11.3 (4.0)
Day 21: mean (SD) 44.2 (20.9) 40.4 (21.5) 7.5 (4.3) 7.1 (4.8)
DiVerence: Day 0–Day 21: mean (SD) ¡23.9 (23.3) ¡26.6 (22.4) ¡4.6 (3.1) ¡4.3 (3.6)
DiVerence: Ibuprofen-Arnica: mean (SD) 3.4 (20.8) ¡0.2 (3.4)
95.2% CI for diVerence [¡2.9; +9.7] [¡1.3; +0.8]
Associated inferiority threshold ¡12.0 ¡3.6
Primary variable test* P(X < Y) + 0.5*P(X = Y) 0.5407 0.4683
95.2% CI [0.455; 0.627] [0.382; 0.554]
Directional test* for Primary Variable 0.5045
For 95.2% CI [0.428;0.581]
Secondary endpoints Ibuprofen gel Arnica gel DiVerence [95% CI]
Number of painful joints ¡2.5 (3.2) ¡3.0 (4.4) 0.4 [¡0.6; +1.4]
Intensity of morning stiVnessa ¡1.0 (0.8) ¡0.9 (1.1) ¡0.1 [¡0.1; +0.2]
Duration of morning stiVnessb ¡0.8 (1.1) ¡0.9 (1.3) 0.0 [¡0.3; +0.3]
Pain (VAS) Hand function (HAI)
Ibuprofen gel 
(n = 98)
Arnica gel 
(n = 100)
Ibuprofen gel 
(n = 98)
Arnica gel 
(n = 100)
ITT population
DiVerence: Day 0–day 21 (SD) ¡22.6 (24.0) ¡25.1 (22.5) ¡4.2 (3.6) ¡4.1 (3.6)
DiVerence: Ibuprofen-Arnica (SD) 2.5 (21.3) ¡0.1 (3.6)
95.2% CI for diVerence [¡3.1; 9.0] [¡1.1; 1.0]
Primary variable test* P(X < Y) + 0.5*P(X = Y) 0.5288 0.4741
95.2% CI [0.448; 0.610] [0.394; 0.555]
Directional test* for Primary variable 0.5015
For 95.2% CI [0.429; 0.574]123
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ommended in osteoarthritis to reduce risk of adverse
events associated systemic administration and to target
local discomfort, particularly to control symptom Xare
up [28]. The analgesic properties of topical NSAIDs in
particular, have been demonstrated with ibuprofen gel
5% (thrice-daily) versus oral ibuprofen (400 mg thrice-
daily) [29]. Finally, our study investigated short-term
use only, but this is in agreement with studies that sug-
gest short-term, such as during Xare ups, is the pre-
ferred setting for gel treatment [27].
While the skin route for medication is long estab-
lished in dermatology, in the last few decades it has
established itself in cardiology (nitrate patches) and it
is gradually becoming common in rheumatology. In
this regard, appropriate testing in methodologically
strict studies is the only way to address, which amongst
the wide variety of agents oVer real beneWt.
In summary, our results show that short-term use,
up to three weeks, of arnica gel improves pain and
function in hand OA, indistinguishably from ibuprofen
gel. Similar eVects are also observed with regard to
number of painful joints, severity and duration of
morning stiVness, as well as the perceived eYcacy by
patients and doctors. Topical application of arnica gel
can be regarded as an alternative to ibuprofen gel
when treating OA of the hand joints.
Table 5 Patients’ and physicians’ evaluations
Good = signiWcant improvement, partial symptoms remis-
sion;Minor = slight improvement, requires other treatments
a Very good = complete or almost complete remission of all
symptoms
Ibuprofen gel 
(n = 85)
Arnica gel 
(n = 89)
n (%) n (%)
Patients’ evaluation of eYcacya
Very good eYcacy 21 (24.7) 27 (30.3)
Good eYcacy 29 (34.1) 30 (33.7)
Minor eYcacy 25 (29.4) 23 (25.8)
Unchanged condition 10 (11.8) 9 (10.1)
Patients’ acceptance of topical treatment
Very satisWed 23 (27.1) 33 (37.1)
SatisWed 42 (49.4) 37 (41.6)
DissatisWed 19 (22.4) 17 (19.1)
Very dissatisWed 1 (1.2) 2 (2.2)
Doctors’ evaluation of eYcacya
Not assessable 0 (0.0) 1 (1.1)
Very good eYcacy 23 (27.1) 27 (30.3)
Good eYcacy 25 (29.4) 30 (33.7)
Minor eYcacy 27 (31.8) 21 (23.6)
Unchanged condition 10 (11.8) 10 (11.2)
Fig. 1 Treatment perceptions by patients and doctors
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Ibuprofen Gel Arnica Gel
By Patients By Doctors
Efficacy Acceptance Efficacy
Table 6 Safety Results
a Possibly, probably or deWnitely related to treatment
b One case of back pain due to fall causing withdrawal from treat-
ment
Ibuprofen 
gel (n = 99)
Arnica 
gel (n = 105)
n (%) n (%)
Patients with any 
adverse event
8 (8.1) 14 (13.3)
Patients with treatment-related 
eventsa
6 (6.1) 5 (4.8)
Patients with serious eventsb – 1(1.0)
Number of events 9 (9.1) 15 (14.3)
Number of treatment-related 
events
7 (7.1) 5 (4.8)
All events’ List
Skin and Hand
Skin irritation/itching (hands) 3 3
Increased Wnger pain 2 2
Reddening 1 1
Scaly skin 1 –
Allergic eczema – 1
Others
Adnexitis 1 –
Chest pain 1 –
Bronchitis – 2
Back pain – 2
Chill – 1
Cystitis – 1
Rhinitis – 1
Vertigo – 1
Total 9 (9.1%) 15 (14.3%)123
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